Real world retrospective study to assess clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) administered with immunotherapy
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Results assessing real impact of immunotherapy, presented at the 2020 World Conference on Lung Cancer.
- 20 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology